Psilocybin and psilocin research index

Select for export

A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues

ABSTRACT Background: Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especia...

Details Copy citation Copy BibTeX

PsyArXiv 2023-10-26 Authors unavailable

PsyArXiv PREPRINT (not peer reviewed) psilocybin DepressionAnxietyEnd-of-Life Distress Systematic Review end of life More

Select for export

Psilocybin as an antidepressant strategy - a review of safety aspects

Introduction Psilocybin is considered a classical psychedelic and is increasingly attracting scientific and media attention as an alternative approach to the treatment of various mental disorders. Apart from its efficacy, an important question is the tolerability and safety of psilocybin in general and in a controlled environment. Accurate knowledge of drug ...

Details Copy citation Copy BibTeX

Unknown journal 2023-07-18 Zeiss R.

Europe PMC Published psilocybin Headache / MigraineReview ArticleSafety Review Article More

Select for export

Psychedelics: Science sabotaged by Social Media.

The substantial challenges facing high and low dose psychedelic drug development to achieve regulatory approval have been documented in the scientific literature. These limitations have not deterred drug developers and social media from repeatedly misleading patients, the public and health professionals. Developing "micro doses" of psychedelics overcomes man...

Details DOI 10.1016/j.neuropharm.2023.109426 PubMed 36693562 Copy citation Copy BibTeX

Unknown journal 2023-01-20 Sellers EM, Romach MK.

Europe PMC Published psilocybin Safety Other Humans More

Select for export

Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.

No single effective therapy for alcohol abuse has been found, despite it being a serious sociological and economic problem for hundreds of years. It seems difficult to find a single drug as a panacea for the alcohol problem due to the complexity of the pathophysiology of alcohol dependence. The purpose of this narrative review is to review existing and poten...

Details DOI 10.3390/ijerph20031870 PubMed 36767234 Copy citation Copy BibTeX

Unknown journal 2023-01-18 Stokłosa I, Więckiewicz G, Stokłosa M, Piegza M, Pudlo R, Gorczyca P.

Europe PMC Published psilocybin Clinical TrialReview Article Clinical Trial Humans More

Select for export

The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics.

Psychedelics were used in the treatment of psychiatric conditions prior to their prohibition in the late 1960s. In the past three decades, there is a revived research interest in the therapeutic potential of psychedelic drugs with expected FDA approvals for treatment of various conditions. Given the exponential scientific growth of this field, we sought to c...

Details DOI 10.1080/02791072.2021.2022254 PubMed 35000572 Copy citation Copy BibTeX

Journal of psychoactive drugs 2022-12-31 Hadar A, David J, Shalit N, Roseman L, Gross R, Sessa B

PubMed Published psilocybin Chronic PainHealthcare Workers Other 3 More

Select for export

A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms

Introduction The 5-HT2A agonist classic psychedelic, psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is a tryptophan, indole-based alkaloid present in up to 2% of certain hallucinogenic “magic” mushroom species; typically Psilocybe azurescens, semilanceata, and cyanescens,. In addition, mushrooms may contain psilocin (4-hydroxy-N,N-dimethyltryptam...

Details Copy citation Copy BibTeX

Unknown journal 2022-08-31 Chue P, Andreiev A, Bucuci E, Els C, Chue J.

Europe PMC Published psilocybinpsilocin PharmacologyReceptor PharmacologyEpigenetics Review Article More

Select for export

Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.

To date, the clinical and scientific literature has best documented the effects of classical psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), in typical quantities most often associated with macrodosing. More recently, however, microdosing with psychedelics has emerged as a social trend and nascent therapeutic...

Details DOI 10.1177/13634615221119386 PubMed 36031848 Copy citation Copy BibTeX

Unknown journal 2022-08-28 Kaypak AC, Raz A.

Europe PMC Published psilocybin MicrodosingCreativitySafety Other Humans More

Select for export

Serotonin toxicity of serotonergic psychedelics.

In recent years, psychedelic substances with serotonergic mechanisms have accumulated substantial evidence that they may provide therapeutic benefits for people suffering with psychiatric symptoms. Psychiatric disorders targeted by these psychedelic-assisted therapies are managed with serotonergic drugs like selective serotonin reuptake inhibitors (SSRIs) as...

Details DOI 10.1007/s00213-021-05876-x PubMed 34251464 Copy citation Copy BibTeX

Psychopharmacology 2022-05-31 Malcolm B, Thomas K

PubMed Published psilocybin NeuroplasticityMechanism of ActionReceptor Pharmacology Review Article Hallucinogen More

Select for export

Beating pain with psychedelics: Matter over mind?

Basic pain research has shed light on key cellular and molecular mechanisms underlying nociceptive and phenomenological aspects of pain. Despite these advances, we still yearn for the discovery of novel therapeutic strategies to address the unmet needs of about 70 % of chronic neuropathic pain patients whose pain fails to respond to opioids as well as to oth...

Details DOI 10.1016/j.neubiorev.2021.12.005 PubMed 34922987 Copy citation Copy BibTeX

Unknown journal 2021-12-15 Elman I, Pustilnik A, Borsook D.

Europe PMC Published psilocybin DepressionAnxietyAddiction Review Article Humans More

Select for export

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.

The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly gaining interest in neuroscience research. Much of this interest stems from recent clinical studies demonstrating that they have a unique ability to improve the debilitating symptoms of major depressive disorder (MDD) long-term after only a single treatment. Indeed, ...

Details DOI 10.1111/jnc.15509 PubMed 34519052 Copy citation Copy BibTeX

Unknown journal 2021-10-21 Kozlowska U, Nichols C, Wiatr K, Figiel M.

Europe PMC Published psilocybin DepressionAddictionNeuroplasticity Clinical Trial Humans More

Select for export

Psychedelics: A new era of treatment?

Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to th...

Details Copy citation Copy BibTeX

Unknown journal 2021-08-12 Torres S.

Europe PMC Published psilocybin DepressionAnxietyAddiction Randomized Controlled Trial More

Select for export

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies

Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has f...

Details DOI 10.1101/2021.04.02.21254838 Copy citation Copy BibTeX

medRxiv 2021-04-06 Gard DE, Pleet MM, Bradley ER, Penn A, Gallenstein ML, Riley LS

medRxiv PREPRINT (not peer reviewed) psilocybin DepressionClinical TrialReview Article Clinical Trial More

Select for export

Sociological investigations of human enhancement drugs: The case of microdosing psychedelics.

Microdosing psychedelics is the regular use of sub-perceptive threshold doses of substances such as lysergic acid diethylamide (LSD) and psilocybin ('magic') mushrooms. The phenomenon has attracted increasing public and scientific attention in numerous countries in recent years. This commentary looks at microdosing psychedelics as an emerging facet of human ...

Details DOI 10.1016/j.drugpo.2020.103099 PubMed 33518382 Copy citation Copy BibTeX

Unknown journal 2021-01-28 Liokaftos D.

Europe PMC Published psilocybin Microdosing Other Humans More

Select for export

The therapeutic potential of microdosing psychedelics in depression.

Microdosing psychedelics is the repeated use of small doses of, for example, lysergic acid diethylamide (LSD) and psilocybin, typically for a few weeks. Despite the popular and scientific attention in recent years, and claims by users that it has therapeutic value in affective disorders like depression, little scientific knowledge is available to back this. ...

Details DOI 10.1177/2045125320950567 PubMed 32922736 Copy citation Copy BibTeX

Unknown journal 2020-08-26 Kuypers KPC.

Europe PMC Published psilocybin DepressionMicrodosingReview Article Review Article More

Select for export

Self-reported negative outcomes of psilocybin users: A quantitative textual analysis

Psilocybin, a substance mainly found in mushrooms of the genus psilocybe, has been historically used for ritualistic, recreational and, more recently, medicinal purposes. The scientific literature suggests low toxicity, low risk of addiction, overdose, or other causes of injury commonly caused by substances of abuse, with growing interest in the use of this ...

Details DOI 10.1371/journal.pone.0229067 PubMed 32084160 Copy citation Copy BibTeX

PLoS ONE 2020-02-20 Bheatrix Bienemann, Nina Stamato Ruschel, Maria Luiza Pesse Campos, Marco Aurélio Negreiros, Daniel C. Mograbi

OpenAlex Published psilocybin DepressionAddictionTreatment-Resistant Depression Other Psilocybin More

Select for export

Hallucinogen persisting perception disorder: A literature review and three case reports.

The paper describes diagnostic criteria, clinical presentation and types of hallucinogen persisting perception disorder (HPPD), as well as current approaches to the treatment of this phenomenon using available scientific sources. Three case reports are also presented to demonstrate different types of this disorder. The first case report describes a 23-year o...

Details DOI 10.1080/10550887.2019.1673655 PubMed 31613183 Copy citation Copy BibTeX

Unknown journal 2018-06-30 Skryabin VY, Vinnikova M, Nenastieva A, Alekseyuk V.

Europe PMC Published psilocybin Review ArticleCase ReportHealthcare Workers Review Article More

Select for export

[New patterns of substance use and abuse among French adolescents, a knowledge synthesis].

AimThere have been significant changes in adolescent consumption habits over the past fifteen years. New molecules have been synthesized, new devices created and a number of products have increased in popularity; and as a result clinicians sometimes lack information. We chose to focus on this population because of its vulnerability, as adolescents show low s...

Details DOI 10.1016/j.encep.2016.05.012 PubMed 27720453 Copy citation Copy BibTeX

Unknown journal 2016-10-05 Jeanne G, Purper-Ouakil D, Rigole H, Franc N.

Europe PMC Published psilocybin AddictionPharmacologyReview Article Review Article Humans More

Select for export

Recreational use, analysis and toxicity of tryptamines.

UnlabelledThe definition New psychoactive substances (NPS) refers to emerging drugs whose chemical structures are similar to other psychoactive compounds but not identical, representing a "legal" alternative to internationally controlled drugs. There are many categories of NPS, such as synthetic cannabinoids, synthetic cathinones, phenylethylamines, piperazi...

Details DOI 10.2174/1570159x13666141210222409 PubMed 26074742 Copy citation Copy BibTeX

Unknown journal 2014-12-31 Tittarelli R, Mannocchi G, Pantano F, Romolo FS.

Europe PMC Published psilocybin PharmacologyMechanism of ActionReceptor Pharmacology Review Article Humans More